Boston Scientific Surges to 118th in Trading Volume Despite Stock Decline

On July 22, 2025, Boston Scientific (BSX) experienced a significant increase in trading volume, with a turnover of $821 million, marking a 42.58% rise from the previous day. This surge placed BSX at the 118th position in terms of daily trading volume. However, despite the high trading activity, the stock price of Boston Scientific declined by 0.60%.

Boston Scientific is scheduled to release its second-quarter earnings report on July 23, 2025, before the market opens. Analysts anticipate that the company will report revenue growth of 18.7%, reaching $4.89 billion, and an increase in earnings per share (EPS) by 16.1%. This growth is primarily driven by the MedSurg segment, which has shown strong performance in recent quarters.

The consensus estimate for EPS is $0.73, representing a 17.7% year-over-year increase, while the consensus revenue estimate is $4.89 billion, a 18.7% year-over-year increase. Over the past two years, Boston Scientific has consistently exceeded EPS estimates, indicating a positive outlook for the upcoming earnings report.

TD Cowen has expressed optimism about Boston Scientific's Q2 performance, expecting the company to surpass estimates and modestly raise its 2025 organic sales growth guidance. Additionally, the firm anticipates an increase in the full-year EPS forecast. This positive outlook is supported by Boston Scientific's resilient performance in a volatile market, with a 20.9% revenue growth and a 27% adjusted EPS increase in the first quarter of 2025.

Boston Scientific's strong performance in the first quarter of 2025, coupled with optimistic analyst estimates, suggests that the company is well-positioned to outperform in the second quarter. The anticipated revenue growth of 17.5-19.5% and organic growth of 13-15%, along with adjusted earnings per share ranging from $0.71 to $0.73, further support this positive outlook. Investors will be closely watching the earnings report to gauge the company's continued success and future prospects.